Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

Tamar Safra; Franco M. Muggia; Susan Jeffers; Denice Tsao‐Wei; Susan Groshen; Olga Lyass; Randal H. Henderson; Gerald J. Berry; Alberto Gabizón

doi:10.1023/a:1008365716693

Keywords

MedicineEjection fractionCardiotoxicityCumulative doseCardiomyopathyHeart failureInternal medicineMitoxantroneDoxorubicinCardiac function curveSurgeryToxicityChemotherapy

Affiliated Institutions

Related Publications

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

Leonard W. Seymour , Karel Ulbrich , Peter S. Steyger +4 more

Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time ...

1994 British Journal of Cancer 163 citations

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Alberto Gabizón

Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique ...

2001 Cancer Investigation 561 citations

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien , Nely Wigler , Moshe Inbar +11 more

2004 Annals of Oncology 1672 citations

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Anne Hamilton , Laura Biganzoli , Robert E. Coleman +9 more

2002 Annals of Oncology 104 citations

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

M. Brada , Khê Hoang‐Xuan , R. Rampling +13 more

Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly establ...

2001 Annals of Oncology 367 citations

Publication Info

Year: 2000
Type: article
Volume: 11
Issue: 8
Pages: 1029-1034
Citations: 605
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

605

OpenAlex

Cite This

APA Style

                            
                                
                                    Tamar Safra, 
                                
                                    Franco M. Muggia, 
                                
                                    Susan Jeffers
                                
                                et al.
                            
                            (2000). 
                            Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. 
                            Annals of Oncology
                            , 11
                            (8)
                            , 1029-1034.
                            https://doi.org/10.1023/a:1008365716693
                        

Identifiers

DOI: 10.1023/a:1008365716693